Conjugate Vaccine Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Conjugate Vaccine Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Conjugate vaccine is a combination of a weak antigen with a strong antigen so to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria.

Market Dynamics

Increasing cases of infectious diseases such as typhoid, pneumonia, and others is expected to drive the global conjugate vaccine growth. For instance, according to a study published in Science Direct Journal in 2017, 11.9 – 26.9 million cases of typhoid fever occur each year in low- and middle-income countries (LMICs) Moreover, as per the WHO 2016 data, around one million children globally die from pneumonia every year and there has been an increasing demand for safe and effective vaccines that could prevent these deaths.

Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination, which in turn contributing to the growth of the global conjugate vaccine market. For instance, on April 25, 2016, innovative smart phones with an app has been provided to various healthcare facilities of northern Mozambique, Africa for 1 year, through the combined partnership of GSK and Vodafone, with funding from GAVI Global Alliance for Vaccines and Immunisation) and USAID (United States Agency for International Development) under mVacciNation pilot program.

This app enables healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.

However, there are some challenges in global implementation of protein conjugate polysaccharide vaccines which may hamper the growth of conjugate vaccine market. For instance, according to the NCBI 2014 article, challenges in implementation of conjugate vaccines includes replacement by nonvaccine serotypes, capsule switching, time duration of the antibody protective effect following vaccination, cost of the vaccines, program costs, lack of knowledge of the disease burden, and targeting population groups for vaccination.

Key features of the study:

  • This report provides in-depth analysis of the global conjugate vaccine market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2018–2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global conjugate vaccine market based on the following parameters – company overview, financial performance, Technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future technology launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global conjugate vaccine market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for global conjugate vaccine market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
  • Global Conjugate vaccine market, By Product Type:
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
  • Global Conjugate vaccine market, By Disease Indication:
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
  • Global Conjugate vaccine market, By Pathogen Type:
  • Bacterial
  • Viral
  • Global Conjugate vaccine market, By Patients Type:
  • Pediatric
  • Adults
  • Global Conjugate vaccine market, By Region:
  • North America
  • By Country:
  • U.S.
  • Canada
  • By Product Type:
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
  • By Disease Indication:
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
  • By Pathogen Type:
  • Bacterial
  • Viral
  • By Patients Type:
  • Pediatric
  • Adults
  • Europe
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • By Product Type:
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
  • By Disease Indication:
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
  • By Pathogen Type:
  • Bacterial
  • Viral
  • By Patients Type:
  • Pediatric
  • Adults
  • Asia Pacific
  • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • By Product Type:
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
  • By Disease Indication:
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
  • By Pathogen Type:
  • Bacterial
  • Viral
  • By Patients Type :
  • Pediatric
  • Adults
  • Latin America
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • By Product Type:
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
  • By Disease Indication:
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
  • By Pathogen Type:
  • Bacterial
  • Viral
  • By Patients Type :
  • Pediatric
  • Adults
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • By Product Type:
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
  • By Disease Indication:
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
  • By Pathogen Type:
  • Bacterial
  • Viral
  • By Patients Type :
  • Pediatric
  • Adults
  • Africa
  • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • By Product Type:
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
  • By Disease Indication:
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
  • By Pathogen Type:
  • Bacterial
  • Viral
  • By Patients Type :
  • Pediatric
  • Adults
  • Company Profiles
  • Sanofi S.A *
  • Company Overview
  • Technology Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Bharat Biotech.
  • Serum institute of India Pvt. Ltd.
  • Biological E. Limited
  • Bio-Med
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Product Type
Market Snippet, By Disease Indication
Market Snippet, By Pathogen Type
Market Snippet, By Patient Type
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Pipeline Analysis
Investments and Government Initiatives
GAVI and PATH Program Details
Merger and Acquisition
Regulatory Scenario
PORTER’S Five Forces
PEST Analysis
4. Global Conjugate Vaccine Market, By Product Type, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Monovalent Conjugate Vaccine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Multivalent Conjugate Vaccine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
5. Global Conjugate Vaccine Market, By Disease Indication, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Pneumococcal
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Influenza
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Meningococcal
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Typhoid
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
6. Global Conjugate Vaccine Market, By Pathogen Type, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Bacterial
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Viral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
7. Global Conjugate Vaccine Market, By Patient Type, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Pediatric
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Adult
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
8. Global Conjugate Vaccine Market, By Regions, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, By Region, 2016 – 2026
Regional Trends
North America
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
U.S.
Canada
Europe
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
GCC Countries
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Million)
Northern Africa
Central Africa
South Africa
9. Competitive Landscape
Heat Map Analysis
Company Profiles
Sanofi S.A.
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Pfizer, Inc.
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Merck & Co., Inc.
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
GlaxoSmithKline plc.
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Bharat Biotech
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Serum institute of India Pvt. Ltd
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Biological E. Limited.
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Bio-Med
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Analyst Views
10. Section
References
Research Methodology
About us and Sales Contact
*Browse 38 market data tables and 33 figures on "Conjugate Vaccine Market” - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook